The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC).
Karim Fizazi
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Julie S. Larsen
Employment or Leadership Position - Janssen Research & Development
Shannon Matheny
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Arturo Molina
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Jinhui Li
Employment or Leadership Position - Janssen Research & Development
Mary Beth Todd
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Margaret K. Yu
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen Research & Development
Thian San Kheoh
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Namphuong Tran
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson